Prevent Acute Chest Syndrome checklist (PACScheck): A quality improvement initiative to reduce acute chest syndrome.
Outcomes research
sickle cell disease
support care
Journal
Pediatric blood & cancer
ISSN: 1545-5017
Titre abrégé: Pediatr Blood Cancer
Pays: United States
ID NLM: 101186624
Informations de publication
Date de publication:
17 Oct 2024
17 Oct 2024
Historique:
revised:
23
09
2024
received:
28
03
2024
accepted:
26
09
2024
medline:
18
10
2024
pubmed:
18
10
2024
entrez:
18
10
2024
Statut:
aheadofprint
Résumé
Acute chest syndrome (ACS) is a life-threatening complication of sickle cell disease (SCD). The Prevent Acute Chest Syndrome checklist (PACScheck) was created to drive appropriate ordering of opioids, incentive spirometry (IS), intravenous fluids (IVF), evaluation of oxygen desaturation, and bronchodilator use. Decrease the development of ACS by 5% in a hospitalized pediatric SCD population. A multidisciplinary team conducted a quality improvement (QI) project between April 2020 and August 2021 on an inpatient pediatric hematology unit. At-risk hospitalizations were patients with SCD who did not have ACS upon hospital admission. PACScheck was implemented and weekly run charts assessed documentation. Process control (p) charts, geometric control (g) charts, and chi-square tests assessed checklist process measures pre- and post-PACScheck. G chart assessed the number of encounters between ACS events. A total of 483 at-risk hospitalizations were identified in the 12 months prior and 363 during the study period. A g chart demonstrated that fewer encounters developed ACS during PACScheck. A p chart demonstrated that IS documentation increased during PACScheck. A run chart of PACScheck documentation demonstrated a median of 100% documentation at least once per hospitalization during the last six months of the intervention. Development of ACS can be reduced by implementing a best-practices checklist (PACScheck) on an inpatient pediatric hematology unit with a multidisciplinary team.
Sections du résumé
BACKGROUND
BACKGROUND
Acute chest syndrome (ACS) is a life-threatening complication of sickle cell disease (SCD). The Prevent Acute Chest Syndrome checklist (PACScheck) was created to drive appropriate ordering of opioids, incentive spirometry (IS), intravenous fluids (IVF), evaluation of oxygen desaturation, and bronchodilator use.
OBJECTIVES
OBJECTIVE
Decrease the development of ACS by 5% in a hospitalized pediatric SCD population.
METHODS
METHODS
A multidisciplinary team conducted a quality improvement (QI) project between April 2020 and August 2021 on an inpatient pediatric hematology unit. At-risk hospitalizations were patients with SCD who did not have ACS upon hospital admission. PACScheck was implemented and weekly run charts assessed documentation. Process control (p) charts, geometric control (g) charts, and chi-square tests assessed checklist process measures pre- and post-PACScheck. G chart assessed the number of encounters between ACS events.
RESULTS
RESULTS
A total of 483 at-risk hospitalizations were identified in the 12 months prior and 363 during the study period. A g chart demonstrated that fewer encounters developed ACS during PACScheck. A p chart demonstrated that IS documentation increased during PACScheck. A run chart of PACScheck documentation demonstrated a median of 100% documentation at least once per hospitalization during the last six months of the intervention.
CONCLUSION
CONCLUSIONS
Development of ACS can be reduced by implementing a best-practices checklist (PACScheck) on an inpatient pediatric hematology unit with a multidisciplinary team.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e31378Subventions
Organisme : Empire Clinical Research Investigators Program
Organisme : EXPLORE Scholar-Agency for Healthcare Research and Quality/Patient-Centered Outcomes Research Institute (AHRQ/PCORI) K12 career development award
Organisme : NIH/National Center for Advancing Translational Science (NCATS) Einstein-Montefiore CTSA
ID : 1UM1TR004400
Informations de copyright
© 2024 Wiley Periodicals LLC.
Références
Darbari DS, Onyekwere O, Nouraie M, et al. Markers of severe vaso‐occlusive painful episode frequency in children and adolescents with sickle cell anemia. J Pediatr. 2012;160:286‐290.
Sachdev V, Rosing DR, Thein SL. Cardiovascular complications of sickle cell disease. Trends Cardiovasc Med. 2021;31:187‐193.
Thein SL, Howard J. How I treat the older adult with sickle cell disease. Blood. 2018;132:1750‐1760.
Hassell KL. Population estimates of sickle cell disease in the U.S. Am J Prev Med. 2010;38:S512‐S521.
Thein MS, Igbineweka NE, Thein SL. Sickle cell disease in the older adult. Pathology (Phila). 2017;49:1‐9.
Vichinsky EP, Neumayr LD, Earles AN, et al. Causes and outcomes of the acute chest syndrome in sickle cell disease. National Acute Chest Syndrome Study Group. N Engl J Med. 2000;342:1855‐1865.
Perronne V, Roberts‐Harewood M, Bachir D, et al. Patterns of mortality in sickle cell disease in adults in France and England. Hematol J. 2002;3:56‐60.
Platt OS, Brambilla DJ, Rosse WF, et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med. 1994;330:1639‐1644.
Vichinsky EP, Styles LA, Colangelo LH, Wright EC, Castro O, Nickerson B. Acute chest syndrome in sickle cell disease: clinical presentation and course. Cooperative Study of Sickle Cell Disease. Blood. 1997;89:1787‐1792.
Adegoke SA, Kuti BP, Omole KO, Smith OS, Oyelami OA, Adeodu OO. Acute chest syndrome in sickle cell anaemia: higher serum levels of interleukin‐8 and highly sensitive C‐reactive proteins are associated with impaired lung function. Paediatr Int Child Health. 2018;38:244‐250.
Jain S, Bakshi N, Krishnamurti L. Acute chest syndrome in children with sickle cell disease. Pediatr Allergy Immunol Pulmonol. 2017;30:191‐201.
Carullo V, Morrone K, Weiss M, et al. Demand‐only patient‐controlled analgesia for treatment of acute vaso‐occlusive pain in sickle cell disease. Pediatr Blood Cancer. 2022;69:e29665.
Miller AC, Gladwin MT. Pulmonary complications of sickle cell disease. Am J Respir Crit Care Med. 2012;185:1154‐1165.
Ojo AS, Ojukwu S, Asmare W, Odipe O, Larbi D. Intravenous fluid administration and the risk of adverse outcomes in sickle cell disease patients hospitalized for vaso‐occlusive crisis. J Hematol. 2022;11:159‐166.
Patterson GD, Mashegu H, Rutherford J, et al. Recurrent acute chest syndrome in pediatric sickle cell disease: clinical features and risk factors. J Pediatr Hematol Oncol. 2018;40:51‐55.
Knight‐Madden JM, Barton‐Gooden A, Weaver SR, Reid M, Greenough A. Mortality, asthma, smoking and acute chest syndrome in young adults with sickle cell disease. Lung. 2013;191:95‐100.
Boyd JH, Macklin EA, Strunk RC, DeBaun MR. Asthma is associated with increased mortality in individuals with sickle cell anemia. Haematologica. 2007;92:1115‐1118.
Yawn BP, Buchanan GR, Afenyi‐Annan AN, et al. Management of sickle cell disease: summary of the 2014 evidence‐based report by expert panel members. JAMA. 2014;312:1033‐1048.
Pronovost P, Needham D, Berenholtz S, et al. An intervention to decrease catheter‐related bloodstream infections in the ICU. N Engl J Med. 2006;355:2725‐2732.
Langley GJMR, Nolan KM, Nolan TW, Norman CL, Provost LP. The improvement guide: a practical approach to enhancing organizational performance. Jossey‐Bass; 2009.
Miller ST, Kim HY, Weiner D, et al. Inpatient management of sickle cell pain: a ‘snapshot’ of current practice. Am J Hematol. 2012;87:333‐336.
Crabtree EA, Mariscalco MM, Hesselgrave J, et al. Improving care for children with sickle cell disease/acute chest syndrome. Pediatrics. 2011;127:e480‐e488.
Bellet PS, Kalinyak KA, Shukla R, Gelfand MJ, Rucknagel DL. Incentive spirometry to prevent acute pulmonary complications in sickle cell diseases. N Engl J Med. 1995;333:699‐703.
Takahashi T, Okubo Y, Handa A. Acute chest syndrome among children hospitalized with vaso‐occlusive crisis: a nationwide study in the United States. Pediatr Blood Cancer. 2018;65.
Takahashi T, Okubo Y, Pereda MA, Handa A, Miller S. Factors associated with mechanical ventilation use in children with sickle cell disease and acute chest syndrome. Pediatr Crit Care Med. 2018;19:801‐809.
George JA, Lin EE, Hanna MN, et al. The effect of intravenous opioid patient‐controlled analgesia with and without background infusion on respiratory depression: a meta‐analysis. J Opioid Manag. 2010;6:47‐54.
Rech JS, Cohen A, Bartolucci P, et al. Shift in emergency department utilization by frequent attendees with sickle cell disease during the COVID‐19 pandemic: a multicentre cohort study. Br J Haematol. 2024;205:463‐472.
Attell BK, Plaxco AP, Zhou M, et al. Emergency department utilization before and during the COVID‐19 pandemic among individuals with sickle cell disease. BMC Emerg Med. 2024;24:134.
Niihara Y, Smith WR, Stark CW. A phase 3 trial of l‐glutamine in sickle cell disease. N Engl J Med. 2018;379:226.
Ogu UO, Thomas M, Chan F, et al. L‐glutamine use in adults with sickle cell disease: clinical trials where success meets reality. Am J Hematol. 2021;96:E38‐E40.